Welcome to our dedicated page for Nexalin Tech SEC filings (Ticker: NXL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nexalin Technology, Inc. filings document a Nasdaq-listed medical technology issuer developing DIFS™ neurostimulation products for mental-health and neurological indications. Its Form 8-K reports cover material agreements for the HALO Clarity pivotal study, Regulation FD clinical-trial updates, Nasdaq listing-compliance notices, equity distribution and at-the-market offering arrangements, and executive employment and equity-compensation matters.
The filing record also documents the company’s common stock and prior warrant securities, including the expiration and delisting of warrants through a Form 25 process. Disclosures identify Nexalin as an emerging growth company and describe governance, capital-structure and corporate-status matters relevant to its public-company reporting.
Nexalin Technology (NXL) filed its Q3 2025 report, highlighting continued operating losses and a going concern warning. Revenue was $18,149 for the quarter, down from $36,031 a year ago, as legacy licensing and equipment sales remained modest. Net loss for Q3 was $2,276,311 versus $2,448,257 in Q3 2024. For the nine months, revenue totaled $129,752 and net loss reached $5,845,635.
Liquidity and capital: Cash and cash equivalents were $590,075 with short‑term investments of $3,762,602, supporting total current assets of $4,817,378 against current liabilities of $357,524. Stockholders’ equity rose to $4,768,416, aided by 2025 equity issuances, including a May/June public offering of 4,090,000 shares with gross proceeds of $5,317,000. The company amended its equity distribution agreement in October to permit ATM sales up to $10,000,000; as of October 15, $4,273,859 remained available under baby shelf limits and 157,000 shares had been sold.
Operations and R&D: Operating expenses were $2,359,832 in Q3, driven by SG&A, salaries, and stock‑based compensation. The company disclosed a substantial accumulated deficit of $90,490,866 and stated there is substantial doubt about its ability to continue as a going concern. On the regulatory front, the FDA accepted a Q‑Submission in October for the Gen‑2 SYNC system targeting Alzheimer’s and dementia, enabling a formal meeting later this year.
Nexalin Technology filed a prospectus supplement for an at-the-market offering of up to $4,273,859 in gross proceeds of common stock, to be sold from time to time through Maxim Group LLC as sales agent under an existing equity distribution agreement.
The filing relies on Form S-3 General Instruction I.B.6, which caps primary sales at one-third of public float. The company reports an estimated public float of $28,772,576 based on 18,189,606 shares outstanding as of September 30, 2025 (with 2,720,479 held by affiliates) and an October 8, 2025 closing price of $1.86. Nexalin has sold approximately $5,317,000 in the past 12 months under I.B.6, leaving $4,273,859 available under this supplement and the Sales Agreement. Shares trade on Nasdaq as NXL; the last reported price on October 14, 2025 was $1.29 per share.
Nexalin Technology, Inc. amended its equity distribution agreement with Maxim Group LLC to expand its at-the-market offering capacity. The amendment increases the aggregate offering price from $3,100,000 to up to $10,000,000 under the ATM Program, allowing the company to sell common stock from time to time through the agent.
As of October 15, 2025, approximately $4,273,859 in aggregate amount of shares remained available for sale under the ATM Program. Sales, if any, will be made pursuant to the company’s effective Form S-3 shelf and a new prospectus supplement dated October 15, 2025.
Nexalin Technology, Inc. (NXL) Form 4 shows Director Leonard Osser (with spouse Marilyn Elson) reported a non-derivative acquisition of 83,333 common shares on 09/29/2025 at a recorded price of $0. After the transaction the reporting parties beneficially own 1,618,577 shares, held directly with shared voting and dispositive power between Mr. Osser and Ms. Elson. The filing is a joint ownership Form 4 and is signed by both reporting persons.
Benjamin Hu, a director of Nexalin Technology, Inc. (NXL), reported the acquisition of 36,459 shares on 09/29/2025. The Form 4 shows the transaction as an acquisition (Code A) with a reported price of $0, and that Mr. Hu now beneficially owns 377,095 shares in total. The filing breaks down those holdings as 372,929 shares held individually by Mr. Hu, 3,582 shares held jointly with his spouse Amy Lun Hu, and 584 shares held jointly with his son David D. Hu. The form is signed by Benjamin Hu on 09/30/2025.
Alan Kazden, a director of Nexalin Technology, Inc. (NXL), reported acquiring additional common stock on 09/29/2025. The Form 4 shows he acquired 36,459 shares with a reported price of $0 and, following the transaction, beneficially owns 119,590 shares. The filing states those shares are held indirectly by the Alan and Natalie Kazden Family Trust and that the reporting person has dispositive and voting control.
The submission is a routine Section 16 disclosure of an ownership change and is signed by Alan Kazden on 09/30/2025. No derivatives, option grants, dispositions, or other transaction types are reported on this Form 4.
Nexalin Technology, Inc. reported material operational and governance details showing continued cash consumption alongside recent equity raises and Nasdaq compliance. The company lost $7.8 million from operations in 2024 and generated negative operating cash flow of $3.94 million, though it reported a working capital surplus of approximately $3.4 million. Shares outstanding increased to 13,303,523 from 7,436,562, including issuance of 3,000,000 shares to investors for net proceeds of $4.52 million and multiple share issuances to Wider and consultants for services and R&D.
The filing discloses internal control weaknesses: insufficient segregation of duties in financial reporting and inadequate IT user/superuser access controls. The company invested $96,000 in a joint venture accounted for under the equity method and wrote off a previously defaulted promissory note principal of $500,000. On July 23, 2024 Nasdaq confirmed compliance with the Minimum Stockholder Equity Rule.
Nexalin Technology, Inc. reports that its publicly traded warrants issued as part of its initial public offering have expired. On September 22, 2025, at 5:00 PM Eastern time, these warrants, each exercisable for one share of common stock at an exercise price of $4.15, terminated in accordance with their original terms.
The Nasdaq Stock Market filed a Form 25 with the SEC to reflect that the warrants had expired and were delisted. The company’s common stock is unaffected by this change and will continue to trade on the Nasdaq Capital Market under the symbol NXL.
Nexalin Technology, Inc. (symbol NXLIW) is the subject of a Form 25 notification filed under the Securities Exchange Act to remove a class of its securities from listing and/or registration on the Nasdaq Stock Market LLC. The filing names the issuer and provides its principal office at 1776 Yorktown, Suite 550, Houston, Texas 77056 and a contact telephone number as listed in the form.
The document duplicates the regulatory checkboxes for rule provisions governing removal and states that Nasdaq certifies it has complied with the applicable procedures to strike or withdraw the class of securities. The form includes the standard OMB approval legend and a note that the Form 25 and attached notice comply with the applicable rules.
Nexalin Technology, Inc. (NXL) filed a Form 144 notice reporting a proposed sale of 23,150 shares of an "Other" class of securities to be executed through Ladenburg Thalmann & Co. Inc. on the NASDAQ with an approximate sale date of 09/10/2025. The filing lists the number of shares outstanding as 1,718,000 and an aggregate market value of 402.81 (as reported). The shares were acquired on 09/16/2022 in an open market purchase from Maxim Group, with payment recorded as cash/check. The filer indicates no securities sold in the past three months and includes the standard representation that the seller is not aware of undisclosed material adverse information.